Known targets — ChEMBL curated mechanism
POLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PRIM1PRIM2RRM1RRM2RRM2B
The experimentally established mechanism targets of Gemcitabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 known ✓ | P09884 | 2/20 | 0.61 |
| ▸ | PDE3A | Q14432 | 3/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | MTOR | P42345 | 1/20 | 0.60 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.60 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.60 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.60 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.49 |
| ▸ | ALB | P02768 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.49 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.49 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.49 |
| ▸ | CDA | P32320 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gemcitabine SCHEMBL19235640 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL6369622 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL13262185 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL12737233 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL19526092 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL17858716 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL12503065 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL249738 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL20827751 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL9143689 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118684726-A | Gly/Ser/Thr-Lys-Arg-Lys-gemcitabine, synthesis, activity and application thereof | 首都医科大学 | 2024-09-24 | — | — | CN | claimed |
| CN-116472064-A | Antibody-drug conjugates and uses thereof | 昆山新蕴达生物科技有限公司 | 2023-07-21 | — | — | CN | claimed |
| CN-108779136-B | Diastereoselective synthesis of phosphate derivatives and gemcitabine prodrug NUC-1031 | 努卡那有限公司 | 2022-07-08 | — | — | CN | claimed |
| EP-4011896-A1 | DIASTEREOSELECTIVE SYNTHESIS OF (SP)-GEMCITABINE-[PHENYL(BENZOXY-L-ALANINYL)]PHOSPHATE NUC-1031 | NuCana plc (GB) | 2022-06-15 | — | — | EP | claimed |
| US-9540412-B2 | Methods of preparing targeted aptamer prodrugs | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. (US) | 2017-01-10 | — | — | US | claimed |
| US-8669377-B2 | Anti-human urothelial carcinoma of supercritical carbon dioxide extract of Cinnamomum subavenium, and the preparation process and uses | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2014-03-11 | — | — | US | claimed |
| US-20130122110-A1 | ANTI-HUMAN UROTHELIAL CARCINOMA OF SUPERCRITICAL CARBON DIOXIDE EXTRACT OF CINNAMOMUM SUBAVENIUM, AND THE PREPARATION PROCESS AND USES | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2013-05-16 | — | — | US | claimed |
| US-20040110718-A1 | Anti-HCV nucleoside derivatives | DEVOS RENE (GB) | 2004-06-10 | — | — | US | claimed |
| US-20030008841-A1 | Anti-HCV nucleoside derivatives | F. HOFFMAN-LA ROCHE, A SWISS COMPANY (CH) | 2003-01-09 | — | — | US | claimed |
| EP-4746876-A1 | UDP-GLUCOSE CERAMIDE GLUCOSYLTRANSFERASE SYNTHASE (UGCG) INHIBITORS IN THE TREATMENT OF CANCER | Katholieke Universiteit Leuven (BE) | 2026-05-27 | — | — | EP | disclosed |
| US-12570684-B2 | DPAGT1 inhibitors of capuramycin analogues and their antimigratory activities of solid tumors | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4637832-A1 | CONJUGATES COMPRISING A PHOSPHORUS(V) MOIETY AND A DRUG | Tubulis GmbH (DE) | 2025-10-29 | — | — | EP | disclosed |
| US-12414996-B2 | Organic anion transporting peptide-based cancer imaging and therapy | Da Zen Theranostics, Inc. (US) | 2025-09-16 | — | — | US | disclosed |
| WO-2025059429-A1 | MODULATORS OF BCL6 FOR USE IN A METHOD OF TREATING A CANCER OR AN AUTOIMMUNE DISEASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-03-20 | — | — | WO | disclosed |
| US-20150005252-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | TILTAN PHARMA LTD. (IL) | 2015-01-01 | — | — | US | disclosed |
| US-8906879-B2 | Combination for the treatment of cancer | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2014-12-09 | — | — | US | disclosed |
| US-8669377-B2 | Anti-human urothelial carcinoma of supercritical carbon dioxide extract of Cinnamomum subavenium, and the preparation process and uses | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2014-03-11 | — | — | US | disclosed |
| US-20130123478-A1 | METHODS OF PREPARING TARGETED APTAMER PRODRUGS | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2013-05-16 | — | — | US | disclosed |
| US-20040110718-A1 | Anti-HCV nucleoside derivatives | DEVOS RENE (GB) | 2004-06-10 | — | — | US | disclosed |
| US-20030008841-A1 | Anti-HCV nucleoside derivatives | F. HOFFMAN-LA ROCHE, A SWISS COMPANY (CH) | 2003-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008841-A1 | Anti-HCV nucleoside derivatives | PNP, HAVCR2, NUDT14 | POLA1 950/4885PDE3A 1257/4885PDE4D 494/4885 |
| US-12414996-B2 | Organic anion transporting peptide-based cancer imaging and therapy | SLC39A3, SLC39A7, SLC43A1 | POLA1 4037/4885PDE3A 4144/4885PDE4D 4705/4885 |
| US-20040110718-A1 | Anti-HCV nucleoside derivatives | PNP, HAVCR2, NUDT14 | POLA1 950/4885PDE3A 1257/4885PDE4D 494/4885 |
| US-12570684-B2 | DPAGT1 inhibitors of capuramycin analogues and their antimigratory activities of solid tumors | DPAGT1, MAGT1, DAD1 | POLA1 1989/4885PDE3A 4101/4885PDE4D 3257/4885 |
| US-20130122110-A1 | ANTI-HUMAN UROTHELIAL CARCINOMA OF SUPERCRITICAL CARBON DIOXIDE EXTRACT OF CINNAMOMUM SUBAVENIUM, AND THE PREPARATION PROCESS AND USES | SUB1, GEMIN5, GEMIN4 | POLA1 682/4885PDE3A 3393/4885PDE4D 4215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.